Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2020-10-16 Director's Dealing
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2020-10-16 English
FORM 3 SUBMISSION
Director's Dealing
2020-10-16 English
FORM 3 SUBMISSION
Director's Dealing
2020-10-16 English
Regulatory Filings 2020
Regulatory Filings
2020-10-15 English
Regulatory Filings 2020
Regulatory Filings
2020-10-14 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1 for Tarsus Pharmaceuticals, Inc. It requests acceleration of the effective date of the Registration Statement and discusses distribution of the Preliminary Prospectus. The document is a correspondence related to the registration and offering process, specifically a request for acceleration under Rule 461 and compliance with Rule 460 and Rule 15c2-8(b). It does not contain financial statements, management discussion, or detailed report content. It is a regulatory filing related to securities registration and offering procedures, not a financial report or announcement of voting results, management changes, or other categories. Given the nature and length (2135 characters), it is best classified as a Regulatory Filing (RNS).
2020-10-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.